Detalle Publicación

ARTÍCULO
Phenotypic, genomic and functional characterization reveals no differences between CD138(++) and CD138(low) subpopulations in multiple myeloma cell lines
Autores: Paino, T.; Sarasquete, M.E.; Paiva, Bruno; Krzeminski, P.; San-Segundo, L.; Corchete, L. A.; Redondo, A.; Garayoa, M.; Garcia-Sanz, R.; Gutierrez, N. C.; Ocio, E. M. ; San Miguel Izquierdo, Jesús
Título de la revista: PLOS ONE
ISSN: 1932-6203
Volumen: 9
Número: 3
Páginas: e92378
Fecha de publicación: 2014
Resumen:
Despite recent advances in the treatment of multiple myeloma (MM), it remains an incurable disease potentially due to the presence of resistant myeloma cancer stem cells (MM-CSC). Although the presence of clonogenic cells in MM was described three decades ago, the phenotype of MM-CSC is still controversial, especially with respect to the expression of syndecan-1 (CD138). Here, we demonstrate the presence of two subpopulations - CD138(++) (95-99%) and CD138(low) (1-5%) - in eight MM cell lines. To find out possible stem-cell-like features, we have phenotypically, genomic and functionally characterized the two subpopulations. Our results show that the minor CD138(low) subpopulation is morphologically identical to the CD138(++) fraction and does not represent a more immature B-cell compartment (with lack of CD19, CD20 and CD27 expression). Moreover, both subpopulations have similar gene expression and genomic profiles. Importantly, both CD138(++) and CD138(low) subpopulations have similar sensitivity to bortezomib, melphalan and doxorubicin. Finally, serial engraftment in CB17-SCID mice shows that CD138(++) as well as CD138(low) cells have self-renewal potential and they are phenotypically interconvertible. Overall, our results differ from previously published data in MM cell lines which attribute a B-cell phenotype to MM-CSC. Future characterization of clonal plasma cell subpopulations in MM patients' samples will guarantee the discovery of more reliable markers able to discriminate true clonogenic myeloma cells.